Oculis Holding AG (FRA:CR5) Change In Receivables : €0.05 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Change In Receivables?

Oculis Holding AG's change in receivables for the quarter that ended in Mar. 2024 was €-0.27 Mil. It means Oculis Holding AG's Accounts Receivable increased by €0.27 Mil from Dec. 2023 to Mar. 2024 .

Oculis Holding AG's change in receivables for the fiscal year that ended in Dec. 2023 was €0.04 Mil. It means Oculis Holding AG's Accounts Receivable declined by €0.04 Mil from Dec. 2022 to Dec. 2023 .

Oculis Holding AG's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oculis Holding AG's liquidation value for the three months ended in Mar. 2024 was €62.38 Mil.

Oculis Holding AG Change In Receivables Historical Data

The historical data trend for Oculis Holding AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Change In Receivables Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

0.21

0.22

-0.15

0.04

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial							-0.26	-0.13	-0.34	0.79	-0.27

Oculis Holding AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05 Mil.

Oculis Holding AG (FRA:CR5) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Oculis Holding AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Oculis Holding AG's accounts receivable are only considered to be worth 75% of book value:

Oculis Holding AG's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	82.758	-	20.375	+	0.75 * 0	+	0.5 * 0
=	62.38

Oculis Holding AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OCS:USA OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines